Technical Analysis for ASMB - Assembly Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ASMB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Outside Day | Range Expansion | -8.14% | |
| Oversold Stochastic | Weakness | -8.14% | |
| Stochastic Buy Signal | Bullish | -9.93% | |
| Oversold Stochastic | Weakness | -9.93% | |
| Gapped Down | Weakness | -6.96% | |
| Lower Bollinger Band Touch | Weakness | -6.96% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakdown | 2 days ago | |
| Gap Down Closed | 3 days ago | |
| 3x Volume Pace | 3 days ago | |
| 2x Volume Pace | 3 days ago | |
| 1.5x Volume Pace | 3 days ago |
Get a Trading Assistant
- Earnings date: 05/07/2020
Assembly Biosciences, Inc. Description
Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Gastrointestinal Gastroenterology Digestive System Digestive System Surgery Fecal Incontinence Gastrointestinal Products Large Intestine Phenylephrine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.84 |
| 52 Week Low | 4.78 |
| Average Volume | 1,214,684 |
| 200-Day Moving Average | 14.59 |
| 50-Day Moving Average | 6.01 |
| 20-Day Moving Average | 5.96 |
| 10-Day Moving Average | 5.76 |
| Average True Range | 0.32 |
| ADX | 19.01 |
| +DI | 17.65 |
| -DI | 32.80 |
| Chandelier Exit (Long, 3 ATRs ) | 6.05 |
| Chandelier Exit (Short, 3 ATRs ) | 6.04 |
| Upper Bollinger Band | 6.74 |
| Lower Bollinger Band | 5.17 |
| Percent B (%b) | -0.06 |
| BandWidth | 26.33 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.09 |
| MACD Histogram | -0.094 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.79 | ||||
| Resistance 3 (R3) | 5.86 | 5.70 | 5.67 | ||
| Resistance 2 (R2) | 5.70 | 5.52 | 5.66 | 5.63 | |
| Resistance 1 (R1) | 5.39 | 5.41 | 5.31 | 5.32 | 5.59 |
| Pivot Point | 5.23 | 5.23 | 5.19 | 5.19 | 5.23 |
| Support 1 (S1) | 4.92 | 5.05 | 4.84 | 4.85 | 4.57 |
| Support 2 (S2) | 4.76 | 4.94 | 4.72 | 4.53 | |
| Support 3 (S3) | 4.45 | 4.76 | 4.49 | ||
| Support 4 (S4) | 4.38 |
